Altre lingue Active Biotech AB

Azioni

ACTI

SE0001137985

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 12:59:51 30/04/2024			Variaz. 5gg	Var. 1 gen.
0,56 ^SEK	+1,82%		+0,18%	+22,67%

03/04	Active Biotech AB (publ) annuncia l'inizio dell'arruolamento nello studio clinico di biodistribuzione di fase I con Laquinimod Gocce Oculari	CI
08/02	Active Biotech AB (publ) riporta i risultati degli utili per il quarto trimestre terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Annual Report 2023 Active Biotech AB (publ)	22/04
Active Biotech announces start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops	03/04
Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops	03/04
Active Biotech Q4 2023 - Three Externally Funded Trials in 2024	09/02
Active Biotech Year End Report 2023	08/02
Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08/02
Active Biotech AB Reports Earnings Results for the Full Year Ended December 31, 2023	08/02
Number of shares and votes in Active Biotech	29/12
Active Biotech provides update on the scheduled clinical program for 2024	22/12
Active Biotech AB Provides Update on the Scheduled Clinical Program for 2024	22/12
Positive preclinical tasquinimod data presented at ASH 2023 now available on Active Biotech’s website	14/12
Active Biotech Raises SEK44 Million via Rights Offering	06/12
Active Biotech announces outcome of the Company’s rights issue	06/12
Active Biotech Teams Up with US Research Group on Clinical Study of Laquinimod Eye Drops	06/12
Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod	05/12
Active Biotech's nomination committee appointed	01/12
Active Biotech AB Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee	01/12
Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis	01/12
Management and members of the board of directors have subscribed for shares in Active Biotech’s ongoing rights issue	29/11
Active Biotech publishes prospectus	13/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Active Biotech AB

Azioni

ACTI

SE0001137985

Altre lingue

Filtri